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Structure-activity analysis of lipopolysaccharide 
immunorecognition by mammalian TLR4/MD-2 complexes
 
The lipopolysaccharide (LPS) of major commensal Gram negative 
bacteria such as enterobacteria or Neisseria is a powerful activator of 
innate immunity in mammalian species acting on a picomolar level as 
pathogen/microbe associated molecular pattern (PAMP/MAMP) via 
molecular recognition of the hexa-acylated and di-phoshorylated lipid 
A domain by the Toll-like receptor 4 (TLR4) / myeloid 
differentiation factor 2 (MD-2) receptor complex [1,2]. The scaffold 
of prototypic Escherichia coli-type lipid A embraces a di-glucosamine 
di-phosphate backbone with a defined membrane anchor structure of 
six aliphatic acyl chains (Figure 1). Beside a core-oligosaccharide, LPS 
typically possesses a variable sugar chain called O-antigen or O-chain 
(Figure 1). Removing both the core-oligosaccharide and the O-chain  
 
 
 
 
 
 
 
 
 
 
 
yields lipid A still capable of inducing endotoxicity (15 in [3]), even 
if exceptions have been reported [4]. 
The innate immune system mediates very effective recognition of 
invading bacteria on a molecular level by receptor/sensor proteins 
localized at the cell surface and intracellular sites. Due to this high 
affinity binding of response triggering bacterial molecules at 
picomolar concentrations, practical laboratory work is driven to the 
cutting edge of what can be achieved technically concerning isolation, 
analysis, purification or contaminants detection. Hence, when 
interpreting bioactivities of LPS, lipid A and LPS/lipid A 
substructures it matters if they are obtained from natural sources or 
chemical synthesis [5]. As revealed in the last two decades, two 
accessory extracellular proteins, LPS-binding protein (LBP) and 
CD14 significantly contribute to the extreme sensitivity of mammlian 
innate immunity to LPS by specific extraction of a single LPS moiety 
from endotoxin aggregates or bacterial membranes and its transfer to 
the TLR4/MD-2 heterodimer [6,7].  
In LPS of wild-type enterobacteria an inner and outer core region 
and the strain-specific O-specific chain have been defined in the 
polysaccharide region based on evolutionary variation. In a set of 
specific enterobacterial glycosyltransferase mutants diplaying a rough 
(R)-type colony form only partial poly/oligo saccharide  structures 
are expressed. 
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Abstract: There is literature evidence gathered throughout the last two decades reflecting unexpected species differences concerning 
the immune response to lipid IVa which provides the opportunity to gain more detailed insight by the molecular modeling 
approach described in this study. Lipid IVa is a tetra-acylated precursor of lipid A in the biosynthesis of lipopolysaccharide (LPS) 
in Gram-negative bacteria. Lipid A of the prototypic E. coli-type is a hexa-acylated structure that acts as an agonist in all tested 
mammalian species by innate immunorecognition via the Toll-like receptor 4 (TLR4)/myeloid differentiation factor 2 (MD-2) 
receptor complex. In contrast, lipid IVa is proinflammatory in mouse cells (agonism) but it remains inactive to human 
macrophages and even antagonizes the action of potent agonists like E. coli-type lipid A. This particular ambivalent activity profile 
of lipid IVa has been confirmed in other mammalian species: in equine cells Lipid IVa also acts in a weak agonistic manner, 
whereas being inactive and antagonizing the lipid A-induced activation of canine TLR4/MD-2. Intriguingly, the respective TLR4 
amino acid sequences of the latter species are more identical to the human (67%, 68%) than to the murine (62%, 58%) ortholog. 
In order to address the unpaired activity-sequence dualism for human, murine, canine and equine species regarding the activity of 
lipid IVa as compared to LPS and lipid A and, we review the literature and computationally pinpoint the differential biological 
effects of lipid IVa versus LPS and lipid A to specific amino acid residues. In contrast to lipid IVa the structurally related synthetic 
compound Eritoran (E5564) acts consistently in an antagonistic manner in these mammalian species and serves as a reference 
ligand for molecular modeling in this study. The combined evaluation of data sets provided by prior studies and in silico homology 
mapping of differential residues of TLR4/MD-2 complexes lends detailed insight into the driving forces of the characteristic 
binding modes of the lipid A domain in LPS and the precursor structure lipid IVa to the receptor complex in individual 
mammalian species. 
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Figure 1. Structures of a typical enterobacterial lipopolysaccharide (LPS), lipid A, precursor lipid IVa (compound 406) and Eritoran (E5564). In their general 
architecture LPS molecules consist of the membrane-anchoring lipid A domain and an oligo- or polysaccharide region of variable length and chemical 
composition (panel A). The prototypic E.coli Lipid A shows a hydrophobic region composed of six (hydroxy-) acyl chains of 12 and 14 carbon atoms (panel B). In 
addition, five experimental values of reduction in human monocyte activation due to the lack of the indicated structural elements are given (panel B). The 
tetra-acylated biosynthetic precursor Lipid IVa of mammalian LPS/lipid A and its synthetic analogue compound 406 are displayed (panel C) next to the tetra-
acyl compound Eritoran (E5564) (panel D). See text for details. 
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For instance, only the inner and outer core parts are present in Ra-
chemotype LPS [8]. The prototypic and also dominant form of E.coli 
Lipid A as represented by its synthetic analog compound 506 consists 
of a β(1´-6) linked backbone of two monophosphorylated 
glucosamines designated as GlcN I and GlcN II and a characteristic 
hydrophobic region composed of six (hydroxyl-) acyl chains of 12 
and 14 carbon atoms (Figure 1, panel B). More in detail, within this 
hexa-acylated structure a subset of four 3-hydroxymyristoyl (3-OH-
C14) residues is attached directly to the β-D-glucosaminyl-(1,6)-β-D-
glucosamine backbone by two amide and two ester bonds at positions 
2/2´and 3/3´, respectively, and the 3-OH-groups of both of the 
´primary´ residues at positions 2´and 3´on GlcN II are further 
esterified to a lauroyl (C12) and a myristoyl (C14) group, respectively. 
The two phosphate residues of the lipid A’s backbone differ 
-glycosidic linkage to the reducing 
monomer (GlcN I) in position C1 of the disaccharide scaffold and 
the other is ester-bound to position 4’ of the nonreducing pyranose 
unit (GlcN II) [9]. The (-) sign marks the 2 and 6 negative charges in 
lipid A and the inner core, respectively. Additionally given (Figure 1, 
panel B) are the approximate numerical values describing the relative 
reduction of human monocyte activation due to the lack of the 
indicated structural elements as measured by comparing the in vitro 
cytokine induction activities of the corresponding synthetic partial 
structures to complete lipid A (compound 506).  
Figure 2. Pairwise superimposition of monomeric units of the murine and human TLR4/MD-2 or MD-2 crystal structures in complex with lipid IVa or LPS/lipid A.  
(A) m(TLR4/MD-2/L4a)2 of 3VQ1 [15] and m(TLR4/MD-2/Re-LPS)2 of 3VQ2 [15] with only lipid A shown. (B) m(TLR4/MD-2/L4a)2 of 3VQ1 [15] and h(MD-2/L4a) 
of 2E59 [11]. (C) h(TLR4/MD-2/Ra-LPS)2of 3FXi [8] and h(MD-2/L4a) of 2E59 [11]. (D) h(TLR4/MD-2/Ra-LPS)2 of 3FXi [8] and m(TLR4/MD-2 /Re-LPS)2 of 3VQ2 
[15] with only lipid A shown. Color codes: Protein backbones are colored in bluish for the solenoid TLR4 ectodomain and in orange/brownish for MD-2 in all 
panels (A-D). In panel A: 3VQ2 appears darker than 3VQ1; in panel B: 2E59; in panel C: 2E59; and in panel D: 3VQ2 again. Ligands: Lipid IVa: always green in 
panels A to C; but yellow for the second lipid IVa in m(TLR4/MD-2/L4a)2 of 3VQ1 [15] in panel B; lipid A partial structure of Re-LPS: yellow in panel A and green 
in panel D. Ra-LPS: yellow (panels C,D). 
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Table 1. Blockwise listing of structure-activity relationships concerning TLR4/MD-2 complexes and its ligand recognition mechanism.
Review on the advances about pattern recognition receptors (PRR) and other concepts of molecular host response to lipopolysaccharide infections. [2]
The major lipid A structure present in Escherichia coli LPS mediates maximal immunoactivation/endotoxiciry (agonism) in mammalian species. E. coli-
type lipid A consists of a central diphosphorylated b-I-4-linked-di-glucosamine backbone carrying a characteristic hexa-acylated hydrophobic unit of
five n-(hydroxy)myristoyl (C'4) residues and one n-lauroyl (Cl2) chain. Both phosphates contribute to the dimerization of the TLR4/MD-2/LPS
complex. LPS of Capnocytophaga canimorsus experiences a 100-fold lower endotoxiciry as E. coli.The lipid A domain present in C. canimorsus LPS has
a penta-acylated monophosphorylated di-glucosamine based structure, i.e. it lacks the corresponding 4' phosphate group of E. coli-type lipid A. More
in detail, a 2,3-diarninoglucosysl residue (GleN-3N) is present in C. canimorsus lipid A and the remaining phosphate in position 1 of the unaltered
glucosamine (GleN-l) is transformed into a phosphoerhanolamine group. It has a core-oligosaccharide attached to its lipid A moiety which possesses
two more zwitter-ionic phosphoethanolamine groups and a negatively charged carboxylate group on Kdo. C. canimorsus lipid A is 20,000-fold less
endotoxic than its lipid A-core oligosaccharide structure. Probably, the missing 4' phosphate is functionally replaced by aforementioned carboxylate as
a prerequisite for lipid A binding to form the MD-2 complex. This is in line with observations (PDB code: 3FXi) that both backbone phosphate
groups of E. coli LPS contact TLR4 and MD-2 through ion bridges or polar hydrogen bond networking.
[4,8,32J
Review of pathogen recognition by TLR proteins and the downstream immune response ofTLR signaling. [35]
The Phe126 loop ofMD-2 undergoes localized structural changes compared to other known human and mouse MD-2. A more comprehensive
description of the horseshoe-like TLR4 and beta-cup folded MD-2 structures is found in the original work of two crystallographer groups.
[11,12J
The crystal structure of chicken MD-l (cMD-l) complexed with lipid IVa is compared with MD-2. The ligand flipping oflipid IVa with respect to
LPS is also discussed. The bound lipid IVa in cMD-l displays the same backbone orientation as elsewhere observed LPS bound to hMD-2. In
contrast, when complexed with hMD-2, lipid IVa is in a reversed orientation of antagonists (Table 4).
[38]
Enzymatic removal of the two phosphate groups on the LPS backbone detoxifies LPS through intestinal phosphatases, i.e. the host can reduce
potentially toxic effects of gram-negative bacteria of the normal bacterial flora of the small intestine.
[39]
The binding of a bacterial diphosphorylmoiety like LPS or lipid A into the ectodornain complex can be seen as a functional analogy to intracellular
signal transduction by protein phosphorylation evidenced by the lower activiry of monophosphoryllipid A or its loss by unphosphorylared derivatives
thereof.
[40]
 
 
5 
Volume No: 5, Issue: 6, February 2013, e201302012 Computational and Structural Biotechnology Journal | www.csbj.org 
The lipid A domain ofLPS interacts with a large hydrophobic pocket ofMD-2. Its glucosamine backbone is phosphorylated on either side. The
docked pose allows both phosphates to form ion bridges to positively charged side chains on TLR4 or MD-2, all ofwhich contribute to complex
formation (see also last table entry).
[8]
Endotoxiciry (agonism) drops when either phosphate group of the diphosphoryl backbone is deleted. [31,44J
Species-dependency differences: Agonistic activities show hexa-acylated lipid A in human, mouse and horse (E. coli), tetra-acylated lipid IVa in mouse
and equine (E. coli), as well as RsDPLA (Rhodopseudomanas sphaeroides, or formerly Rhodobactersphaeroides) in equine and hamster. In contrast
antagonists are lipid IVa in human or Eritoran in all three species (hrne).
[46,45,40J
A hexa-acylated form of Pseudomonas aeruginosa (Pa) LPS-mediated induces much stronger pro-inflammatory responses in human cells than the
corresponding penta-acylated form of Pa-LPS. In contrast, the difference in bioactivity of penta- versushexa -acylated LPS was significantly less
expressed in HEK-293 cells transfected with murine TLR4. A chimeric variant of human TLR4 containing a 82 amino acid segment of murine TLR4
(mTLR4: 287 to 368) results in 'murine-type' reaction pattern in the comparison of penta- and hexa-acylated LPS structures. Note: our inspection of
the area on crystal structure 3FXI shows that several of these amino acid residues are positioned in the TLR4 interface contacting the hydrophilic
ligand backbone above the MD-2 pocket and also parts of the dimerization interface of counter-TLR4.
[47]
Certain derivatives of LPS were identified as inhibiting agents or agonists according to the applied cell tests. The existence of traces of the highly potent
LPS could lead to false positive activity observations in analogy to the residual presence of lipoproteins in reported cases ofTLR2-activating LPS
preparations. Meanwhile, the situation has improved with the advent of newer analytical technologies to identify and purify smallest amounts of test
substances in the picomolar range. A further complication in understanding lipid A biology is its heterogeneity due to natural variations like penta or
hexa-acylated forms found in lab strains. Many experiments use lipid A from lab strains that contain a structural mixture (number and length of lipid
chains). LPS isolated from Porpbyromonas gingivalis is highly heterogeneous, which possibly accounts for reports that P. gingivalis LPS can activate two
innate immune receptors simultaneously. Inflammatory response by Lipid A from Pseudomonas aeruginosa is less than that of enterobacterial E. coli
LPS.
[2,3,30],
All fatty acids of both antagonists are docked deeply into the hydrophobic binding pocket ofMD-2. Quite in contrast, the LPS complex shows an
unburied primary fatry acid chain (FA-1 of LPS) not observed in both antagonist complexes. [7,8]
Review about the TLR2 agonist activities of certain putative bacterial compounds is most likely due to contaminating highly active natural lipoproteins
and/or lipopeptides. Endotoxiciry strength ofLPS with 6 fatty acids (FA) is larger than other derivatives with 5 FA or others with just 4 FA. The acyl
chain length is longer on LPS from E. coli than that of Pseudomonas aeruginosa.
[30]
 
As compared to the ubiquitous activation of mammalian 
TLR4/MD-2 signaling by enterobacterial LPS or lipid A, particular 
lipid A substructures like the tetra-acylated biosynthetic precursor 
Lipid IVa or its synthetic analogue compound 406 act either as 
antagonists or weak receptor agonists in a species-dependent manner 
(Figure 1, panel C). In contrast, the tetra-acyl compound Eritoran 
(E5564) acts as a TLR4/MD-2 receptor antagonist in all 
mammalian species investigated to date (Figure 1, panel D).  
The lipid A-specific interaction between the complex of the 
solenoid TLR4 ectodomain and MD-2 with LPS induces a 
rearrangement and dimerization to an “m-shaped” signaling complex 
of two TLR4/MD-2/LPS units [8] (Figure 2). This LPS/lipid A-
induced formation of the dimeric (TLR4/MD-2/LPS)2 complex on 
the cellular surface constitutes a key step to activate the innate 
immune system in mammalian species [9,10]. In addition, X-ray 
crystal structures of human MD-2 either alone or in an 1:1 
association with a partial structure of the human TLR4 ectodomain 
have shown that the tetra-acylated ligands lipid IVa and Eritoran also 
bind to the central binding cleft of human MD-2, but in a largely 
different and thus non-agonistic orientation as compared to the lipid 
A domain of LPS [11,12]. Furthermore, x-ray structural data of the 
radioprotective 105 kDa (RP105) ectodomain/ myeloid 
differentiation factor 1 (MD-1) complex representing a major 
negative feed-back-regulatory element of LPS-induced TLR4/MD-
2-signaling have revealed a ligand-independent dimer formation of 
two RP105/MD-1 units in an inverse orientation as compared to the 
(TLR4/MD-2-LPS)2 complex [13,14].  
In general, loss of one or both phosphate groups, underacylation 
and/or the replacement of single or multiple acyl residues within the 
characteristic pattern of five n-(hydroxy)myristoyl chains plus one n-
lauroyl residue by shorter acyl chains lead to partial or total loss of 
immunoactivity [5,16-30]. The binding to TLR4/MD-2 is 
TLR4 / MD-2 receptor complexes 
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Diphosphoryllipid A obtained from the nontoxic
lipo-polysaccharide of Rhodopseudomona ssphaeroides is
an endotoxin antagonist in mice.
RSLA blocks LPS activity of E. coli in vitro and in uiuo (mouse organism). Description of SAR:
lipid A of is the active part of LPS. In general, lipid A with higher or lower FA content and a
single phosphate group is less active.
[40]
Structural regions ofMD-2 that determine the
agonist-antagonist activity of lipid IV A.
The species-specific activity of lipid IVa reflects species differences in mouse and humanMD-2
structures. Amino acid regions 57-79 and 108-135 determine the species-specific activity oflipid
IVa. The replacement ofThr57, Val61, and Glul22 of mMD-2 with corresponding hMD-2
residues Ser57, Leu61 and Lys122 or alanines impaired the mouse-type agonistic activity of lipid
IVa, and human-type antagonistic activity became evident.
[36]
Essential roles of hydrophobic residues in both MD-2
and Toll-like receptor 4 in activation by endotoxin.
The role of acyl chains of lipid A and lipid IVa, in particular, FA1 in the interface of human and
murine MD-2 counter TLR4, respectively.
[8,15]
Essential roles of hydrophobic residues in both MD-2
and toll-like receptor 4 in activation by endotoxin.
In the human TLR4 sequence, Phe440 and Phe463 of counter TLR4 (B chain) as well as three
hydrophobic amino acids Va182, Met85, and Leu87 ofMD-2 (C chain) together with a fatty acid
side chain of hexa-acylated lipid A form a hydrophobic interface between TLR4/MD-2 and
counter-TLR4 for innate immune activation. Mutations ofPhe440A or Phe463A render TLR4
unresponsive, whereas the Phe440Trp mutant retained full activity. B chain Lys388 is considered
irrelevant in contrast to reports by Meng et al.
[8,37]
completely lost when both of the two phosphate groups are removed 
indicating their importance for providing binding affinity in all partial 
structures of enterobacterial lipid A tested [16,24,31]. The activity is, 
however, preserved when a carboxyl group replaces the phosphate 
group on LPS [32]. This indicates a major contribution of negative 
charges in lipid A-binding to TLR4/MD-2 mediated by positively 
charged amino acids on TLR4 and MD-2. Another example of a 
lipid A derivative/partial structure with reduced overall negative 
charge is 4´-monophosphoryl lipid A (MPLA), which has been 
shown to display markedly reduced TLR4/MD-2 agonistic activity 
as compared to the diphosphorylated lipid A parent structure. Binding 
of these ligands to the receptor binding site leads to only partial 
activation of the TLR4/MD-2-connected intracellular signaling 
network of as compared to the full agonist (lipid A), thus resulting in 
incomplete signaling [28]. In comparison to lipid A, 4´-
monophosphoryl lipid A (MPLA) lacks one phosphate group and is 
therefore unable to contact some positively charged residues on the 
surface of both MD-2 and TLR4 [2,8]. Recently, it was observed 
that the presence or absence of the oligosaccharide core segment from 
Capnocytophaga canimorsus LPS modulates endotoxic potency 
(Table 1). The structural implications were also discussed based on 
molecular dynamics simulations of the liganded human MD-2 
monomer with lipid A from C. canimorsus and E. coli [4].  
 
Site-directed mutagenesis data of liganded TLR4/MD-2 
complexes 
 
Various lipid A derivatives or analogous agents (Figure 1) with a 
common amphipathic glycolipid scaffold have been described to 
represent LPS/lipid A-like activators (agonists) or TLR4/MD-2 
signaling or inhibitors (antagonists) of LPS-induced cellular 
immunoactivities [2,25,28,49,50]. LPS receptor inhibitors are being 
developed as potential drugs for adjunct treatment of septic shock 
patients with Gram-negative septic infection (endotoxicity). Lipid 
IVa, a tetra-acylated lipopolysaccharide precursor in the biosynthesis 
of Escherichia coli or Salmonella lipid A, is an agonist in murine 
myeloid cells but it remains inactive to human macrophages and even 
antagonizes the action of potent agonists like E. coli-type hexa-
acylated LA. In contrast to lipid IVa, however, the synthetic 
compound Eritoran that also comprises of only four acyl chains is a 
potent TLR4/MD-2 receptor antagonist in human, murine and 
equine species and can be considered as an investigational drug against 
bacterial sepsis [2], (48,51,75 in [46]). 
Site directed mutagenesis approaches have revealed involvement of 
species-specific residues in MD-2 [36] and TLR4 in 
agonistic/antagonistic activities of lipid IVa (Table 2) [8,37,51, 52]. 
Hence these mutagenesis data indicate, that both MD-2 and TLR4 
contribute to the species-specific response to lipid IVa 
[12,15,36,37,53,54]. For example Thr57, Val61, and Glu122 of 
mouse MD-2 may have an impact on activation of the murine 
receptor complex by lipid IVa [36]. TLR4 was also subject to a set of 
selective human/horse sequence conversion mutants like R385G 
[51,52].  
 
Dimerization and activities in crystal structures 
 
With the 2012 release of the crystal structures of the mouse 
TLR4/MD-2/L4a and TLR4/MD-2/Re-LPS complexes (PDB 
codes: 3VQ1, 3VQ2) [15] it became possible to compare two 
complementary functional pairs (Table 3): (i) agonistic dimeric 
murine (TLR4/MD-2/L4a)2 [15] versus the antagonistic monomeric 
human (MD-2/L4a)1 complex [11]; as well as (ii) agonistic dimeric 
human (TLR4/MD-2/Ra-LPS)2 [8] versus the antagonistic 
monomeric human (MD-2/L4a) complex [11].  
The oligomerization state is different for the liganded and 
unliganded complexes and it also depend on the environment: In 
2007 it was described that LPS binding induces the dimerization of 
hTLR4/MD-2 [55]. Crystallography (Table 3) showed 
unambiguously the dimeric structures of human (TLR4/MD-
2/LPS)2 [48] and mouse (TLR4/MD-2/LPS)2 complexes [15]. In 
native gel electrophoresis experiments the complex was shown to be a 
dimer: m(TLR4/MD-2/Re-LPS)2. In contrast, when bound to lipid 
IVa the complex remained monomeric m(TLR4/MD-2/L4a) in 
solution according to the electrophoretic mobility shift data. 
However, the lipid IVa murine complex was dimeric in the crystal 
form: (TLR4/MD-2/L4a)2 [15]. The authors ascribe its missing 
dimerization in solution to weaker noncovalent forces in the 
dimerization interface, assuming that the dimerization would be 
enhanced in the membrane where movements are restricted to the cell 
surface to facilitate contacts. If this holds, then the structural events as 
observed by crystallography of mouse (TLR4/MD-2/L4a)2 and 
human MD-2/L4a monomer are in close keeping with the biological 
function of either agonism (mouse) or antagonism (in human cells).  
As pointed out by Park and colleagues [8] the initial comparison 
of the human dimeric (TLR4/MD-2/Ra-LPS)2 crystal structure 
(PDB code: 3FXI) with the monomeric antagonist complexes of lipid 
IVa with human MD-2 (PDB code: 2E59) and Eritoran with a 
TLR4/MD-2 fragment (PDB code: 2Z65), revealed that the 
presence of the two additional (secondary) acyl residues in the lipid A 
domain of Ra-LPS is correlated with a relative upward shift of the di-
phosphorylated glucosamine backbone by approximately 5 Å towards 
the solvent area. This structural shift allows phosphate groups of LPS 
to contribute to receptor multimerization by forming ionic 
interactions with a cluster of positively charged residues in human 
TLR4 and MD-2. The results of the pairwise superimposition of this 
set of four crystal structures (Table 4) were visualized (Figure 2). 
 
Dimerization and signaling 
 
Mechanistically different aspects of signaling are in discussion: 
ligand-induced oligomerization, cytoplasmically driven self-
association or agonistic dimerization [15,20,56]. LPS binding to the 
cell surface receptor TLR4 constitutes the extremely specific and 
effective agonistic stimulus for transmembrane signaling via 
connecting Toll/IL-1R endodomain (TIR) to mount an immediate 
immune response. Intriguingly, recent experiments on replacement of 
the TLR4 ectodomain with MD-2, CD14, monomeric fluorescent 
protein or a 24 kDa gyrase B fragment revealed a robust ligand-
independent constitutive activation of signaling by the corresponding 
chimeric fusion proteins, comparable to the maximal stimulation of 
the receptor with LPS. As discussed by the authors this indication for 
an intrinsic dimerization propensity of the transmembrane and 
cytoplasmic domains of TLR4 and reveals a previously unknown 
function of the ectodomain in inhibiting spontaneous receptor 
dimerization, since the unliganded TRL4 receptor complex must be 
kept in an inactive state without release of undesired immune 
responses [57]. 
In 2009, Meng et al. published mutational observations about 
important residues on the TLR4/MD-2 protein complex which were 
animated through our SPL scripting in the 3D models (Table 5) [37]. 
Surprisingly, the equine residues are identical with human residues 
contrary to what could be expected from their activity differences 
concerning lipid IVa. It acts as an antagonist in human cell tests but 
as a full or partial agonist in mouse or horse systems, respectively.  
TLR4 / MD-2 receptor complexes 
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More in detail, the backbones substructures of agonists were 
consistently found to display an orientation with the reducing 
glucosamine-1-phosphate unit facing the secondary (signaling) 
dimerization site at the open side of the MD-2 pocket, whereas the 
antagonists were consistently crystallized in the inverted backbone 
orientation, rotated (´flipped´) by 180° as compared to the agonistic 
ligands. Moreover, the hydrophilic backbone structures of all 
agonistic ligands have been found to be placed in a significantly 
upward shifted position relative to MD-2 surface as compared to the 
antagonists.  
Now, it is to say, that contrary to classical pharmacology, where 
drugs act as either (full or partial) agonists or antagonists, lipid IVa 
acts either as an antagonist or an agonist in a characteristic species-
dependent manner. Evidently, there is not a corresponding ´classical´ 
structure-activity relationship for lipid IVa, since the ligand structure 
is the same. However, a correlation has been revealed between the 
species-characteristic agonist versus antagonist activities of lipid IVa 
and the overall binding mode this particular ligand i.e. how deep lipid 
IVa is buried in the MD-2 pocket and which mode of backbone 
orientation is present along the binding cleft. Apparently, when this 
tetra-acylated ligand binds very deeply into the pocket, then the 
specific unit of one phosphate group (and/or any acyl equivalent 
nearby, KDO) is not exposed on the dimerization side of the 
TLR4/MD-2/L4a monomer in order to attract a second monomer. 
This species-related TLR4/MD-2/L4a monomer thus fails in 
attracting a second monomer to initiate dimerization and consecutive 
downstream signaling. 
 
TLR4 / MD-2 receptor complexes 
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PDBCode
Year
Ref
2E59
2006
[IIJ
2E56
2006
[l1J
2Z62
2007
[12J
2Z63
2007
[12J
2Z64
2007
[9J
2Z65
2007
[I2J
2Z66
2007
[12]
3FXI
2009
[8J
3MU3
2010
[13]
3MTX
2010
[I3J
3VQl
2012
[15]
3VQ2
2012
[15]
Species (Components in complex)
TITLE
Human (MD-2 / L4a),
CRYSTAL STRUCTURE OF HUMAN MD-2 IN COMPLEX WITH LIPID IVA
Human (MD-2li
CRYSTAL STRUCTURE OF HUMAN MD-2
Human (TLR4 fragment)'
CRYSTAL STRUCTURE OF THE TV3 HYBRID OF HUMAN TLR4 AND HAGFISH VLRB.61
Human (TLR4 fragment)l
CRYSTAL STRUCTURE OF THE TV8 HYBRID OF HUMAN TLR4 AND HAGFISH VLRB.61
Mouse (TLR4 fragment / MD-2),
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In this view, lipid IVa appears to be rather an imperfect agonist 
than an agent with dual activity. As a comparably lower affinity 
ligand, it can bind in species-dependent manner either in an agonistic 
orientation (with its more surface-exposed backbone as found in the 
murine receptor complex) or the antagonistic orientation (with the 
flipped or inversed di-phospho-di-glucosamine backbone as revealed 
for the monomeric human MD-2 complex).  
The earlier reviewed literature attests that lipid IVa is an agonist 
in mouse but acts as an antagonist in human cells. It can be assumed, 
that binding of agonists lead to a dimerization of liganded Toll-like 
receptor 4 and myeloid differentiation factor 2 complexes which then 
triggers downstream signaling for anti-inflammatory response. 
Cytoplasmically-driven self-association was, however, also reported. 
Based on the x-ray crystal structures of dimeric TLR4/MD-
2*agonist complexes the presentation of the three protein chains in 
the region of the dimerization interface, i.e. TLR4 (chain A), MD-2 
(chain B) and TLR4* (chain C, ´counter´ TLR4) as a triangular 
interaction zone (“wedge”) is a most useful concept to analyze species 
differences and to predict mutational effects (Figure 3). In this 
structural selection  the wedge-like area consists of three sides: two 
partial structures of TLR4 proteins contributing to the ´primary´ and 
´seondary´dimerization interfaces and one MD-2 forming the 
connecting bottom line. On a molecular level the species-dependent 
activity profiles of lipid IVa are reflected by a concert of conserved 
and variable amino acids in their respective protein sequences in this 
wegde-shaped zone.  
 
Dimerization and activity 
 
The differential height of the phosphates above the wedge bottom 
(MD-2) directly reflects the activity changes between the species. 
Only a highly exposed phosphate group of the backbone is capable of 
linking two liganded TLR4/MD-2 units [8]. Hence, this site 
(labeled as “Pag” in Figure 3) is considered to play the key role for 
switching to agonism (Pag) from antagonism (Pan) and back. While 
the Pag site contacts the GlcN I phosphate group of all observed 
agonists, the Pan site interacts with the GlcN II phosphate group of 
all antagonists as the latter show a flipped backbone.  
According to the binding models the equine residue pair 
eGly322A & eGlu344A at the TLR4 interface corresponds to 
hGlu321A & hGly343A or mLys319A & mLys341A of the human 
and murine systems, respectively (Figure 3). The former two pairs are 
interrelated in a homologous way. The murine pair differs by two 
cationic residues and stabilizes the phosphate group in its agonistic 
site. Moreover, this pair together with others (nonconserved hGly384 
vs. mAla382 vs. eArg385) nicely explain the crystallographically 
observed shift in the wedge’s leftmost phosphate groups from a MD-
2 assisted antagonistic phosphate binding site (interacting 
hARG90C) toward the agonistic phosphate site.  
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Park et al. already mentioned the relevant phosphate bridging of 
liganded TLR4/MD-2 unit (chains A,C) toward a second or 
counter-TLR4 (chain B) in the wedge, a concert of interacting 
residues assists the dimerization interface (Figure 3). It can be 
assumed that homodimerization is signaling relevant, since agonistic 
lipid IVa appears as (TLR4/MD-2/L4a)2 in mouse complexes [14] 
which parallels agonistic LPS bound to mouse and human crystal 
complexes [8,14]. Very close to the wedge lies a histidine-rich surface 
patch (never referred to) in the dimerization interface of the two 
TLR4 proteins (chain A and chain B of 3D template 3FXI [8], which 
is the counter TLR4, sometimes labeled as TLR4* in the literature). 
This dimerization interface probably plays a role in transmembrane 
signal transduction.  
 
Conclusions 
 
During eons only LPS has been relevant for evolutionary 
adaptation. During time any random mutations were kept in the genes 
if they were not detrimental to the LPS recognition (silent point 
mutations) with the present day consequence that all nonidentical 
residues in MD-2 and TLR4 sequences do not affect picomolar LPS 
recognition. However, this is not the case of synthetic lipid IVa which 
is also a biosynthetic interim in bacterial cells. The hitherto silent 
mutations for LPS in mammalians become relevant for lipid IVa. 
Mapping makes the interacting net of amino acids recognizable 
(Figure 3). The homodimerization process in mice is helped by a 
nonconserved nonpolar residue (mAla414B) sitting in opposition to 
what would be the antagonistic phosphate (Pan) on (counter) 
TLR4*. Thanks to the nonpolar alanine - anionic repulsion, the 
phosphate group becomes a theoretical “rejection group” and the 
phosphate group moves into its agonist position further up as an 
accessible alternative, which actually is the only solution in the wedge. 
In its linear elongated conformation the mArg434B can interact with 
the phosphate group in agonist position. This amino acid is not 
conserved in horse, but compensated through the presence of 
eArg385A which moves the phosphate group into an “in-between 
pose” between aforementioned agonistic phosphate in the upper left 
corner of the wedge and its antagonistic counterpart in its lower left 
corner. 
Taken together the collected data in a more general view, binding 
of agonists to TLR4/MD-2 leads to formation of a dimeric 
(TLR4/MD-2/Ligand)2 complex that efficiently activates 
downstream signaling to activate the vertebrate innate immune 
response while antagonists act as competitive inhibitors of agonists by 
binding to the monomeric TLR4/MD-2 unit in a non-dimerizing 
and thus non-signaling, hence, unproductive manner. Drawn from the 
hitherto known crystal structures, there is a complex correlation 
between binding and biological function regarding the exact ligand 
positioning and in particular the stretched diphophosphorylated di-
glucosamine backbone spanning the width of the MD-2 unit reaching 
from one TLR4 to the other (counter) TLR4* in view of the 
changing agonistic versus antagonistic activities of complexed ligands. 
All agonist ligands have been shown to mediate a specific bridging of 
two TLR4/MD-2 subunits to dimeric complexes (TLR4/MD-
2/Lig)2 in the crystal structures whereas the antagonists apparently do 
not provide the dimerization of TLR4/MD-2 complexes. A crucial 
finding is the recognition of a murine acidic residue in the otherwise 
basic vestibule of MD-2. It leads to a repulsion and phosphate shift 
into agonist position which enables the ligand backbone to bridge 
both TLR4/MD-2 units. The right corner of the wedge (Figure 3) is 
highly conserved and holds the GlcN II phosphate group of agonists 
or, GlcN1 phosphate of antagonists due to their flipped backbones. 
This is why liganded TLR4/MD-2 forms most likely the functional 
biological unit. Hence, it must be considered a “monomer” (strangely, 
a heteromonomer, so to speak). It constitutes the “attachment point” 
or devise for the association of another liganded TLR4/MD-2 unit 
to form the signaling dimer.  
Figure 3. Schematic view of the wedge, a triangular space between the three interacting polypeptide chains, A, B and C corresponding to TLR4, secondary or 
counter-TLR4 (labeled TLR4*) and MD-2 proteins, respectively. The numbering of the TLR4 residues refers to the horse sequence. Due to deletions of a few 
TLR4 residues their numbers differ slightly at equivalent positions: up to equine position number 297: e=h=c=m+1; then from equine position 298 to 560: e = 
m+3 = h+1 = c+1 or h=m+2=e-1=c-1. For instance, comparison of the residues present in (equine) position 322A indicates repulsion effects for the agonistic 
phosphate group (Pag) of lipid IVa in human (Glu-321A) and canine (Asp-321A) complexes, but strong attraction for murine (Lys-319A) and less for equine (Gly-
322A) systems. In mice, the positions 367B and 434B push the phosphate group into Pag. Position 367B destabilizes Pag as phosphate localization in human, 
equine and canine systems. On the wedge bottom, MD-2 has a cation-reach vestibule to accommodate (Pag-rejected) phosphate groups in Pan except for mice 
(mGLU122C). Surrounded by conserved residues, Pag/Pan always accommodates the other (second) phosphate group of lipid IVa. The Pan position is occupied 
by the GlcN II phosphate group of lipid IVa or Eritoran, while the GlcN I phosphate group of LPS / lipid A occupies Pag. In the highly conserved right corner of 
the wedge is the all species-shared Pag-Pan site holding the complementary phosphate groups of the backbones: either GlcN I phosphate group for lipid IVa 
and Eritoran, or GlcN II phosphate group for LPS and lipid A. 
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